Clinical Pipeline Affimed is a clinical-stage immuno-oncology company with three active ICE programs (AFM13, AFM24, AFM28) spanning hematologic and solid tumors, offering multiple collaboration and co-development opportunities with cell therapy partners, ICOs, and pharmaceutical companies seeking combination strategies.

Partnerships & Co-Development Strategic collaborations are a strong sales lever, notably with AlloNK AB-101 and NK cell platforms, plus potential for modified ICE molecules to pair with existing I-O assets, enabling BD teams to pitch combination therapies and off-the-shelf cellular strategies to large biopharma and specialty biotech sponsors.

Clinical Evidence Recent data showing higher AFM24 exposure correlates with improved response rates and progression-free survival in NSCLC strengthens the case for dose-optimization partnerships and co-development deals around PK/PD-driven regimens and companion diagnostics.

Market Positioning Affimed focuses on innate immune engagement using the ROCK platform to mobilize NK cells and macrophages, highlighting a differentiated mechanism for tumor targeting in both hematologic and solid tumors, a compelling message for asset-light collaborations and licensing discussions.

Financial & Growth Signals Despite Nasdaq delisting and insolvency proceedings filings in 2025, ongoing clinical activity and published abstracts at AACR and ASCO indicate continued R&D momentum, presenting opportunities for distressed asset discussions, potential license-outs, or strategic investments to accelerate the pipeline.